Pharma Expenditures Keep Rising - Pharmaceutical Executive

ADVERTISEMENT

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Pharma Expenditures Keep Rising
May 1, 2002
By: Jill Wechsler
Pharmaceutical Executive

The National Institute of Health Care Management made headlines with its report on double-digit increases (17 percent) in retail spending on medicines in 2001. The total reached $155 billion last year, almost double the $80 billion spent in 1997, according to the study, "Another Year of Escalating Costs." PhRMA president Alan Holmer said the increase is a good thing, signifying that more people who need medicines for chronic conditions are being treated and thereby avoiding more expensive medical procedures.


US. Retail Spending on Perscription Drugs
The report identifies three factors responsible for more spending: an increase in prescribing (39 percent), price hikes (37 percent), and a shift to more expensive drugs (24 percent). The "shift effect" to pricier products was only 24 percent last year, compared with 36 percent from 1999 to 2000, largely because fewer new blockbusters came on the market. Also, the pace of growth may be slowing. Last year's 17 percent increase is less than the 18-19 percent hikes of previous years. But spending could shoot up if the government expands coverage for Medicare beneficiaries .

Even if drug outlays rise more slowly, they still will exceed the growth in spending on physicians and hospitals. Several factors will continue to drive pharmaceutical spend, including expanded use of medicines to treat chronic conditions, increased prescribing by physicians, and heavy marketing of new products.

ADVERTISEMENT

About the Author

Jill Wechsler

Washington Editor

Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on government policies and a wide range of topics for business and consumer publications. Articles by Jill Wechsler

post a comment
Please complete the form below to post your comment.
Bold = Required
Email Address Your email address will NOT be published.
Display Name appears with your comment
City
State
Country
Remember me: YesNo
Comment read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
FindPharma Careers
Featured Jobs

More Jobs

5/1/2002
Click here